Drug Trial Radar · NCT05689853
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
87
Planned (sponsor's estimate)
Start
Apr 14, 2023
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Jan 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.
Conditions
- Solid Tumor, Adult
Interventions
AK119Drug
AK119 is an anti-CD73 monoclonal antibody.
AK112Drug
AK112 is a bispecific monoclonal antibody against VEGF and PD-1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with dose limiting toxicities (DLTs)Time frame: During the first three weeks
- Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug.
- Objective Response Rate (ORR)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.